Why Regenxbio Halted Its Gene Therapy Trial—and Why the Stock Is Tumbling
Yahoo Finance · Aug 24, 2026 · Sarepta Therapeutics Inc (SRPT)
Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company’s investigational therapy for Hunter syndome.
Not investment advice. Cached headline, not a full reprint.